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2Abstract
In addition to increased aberrant protein aggregation, inflammation has been proposed as a 
key element in the pathogenesis and progression of Alzheimers disease. How inflammation 
interacts with other disease pathways and how protein aggregation increases during disease 
are not clear. We used single molecule imaging approaches and membrane permeabilisation 
assays to determine the effect of chronic exposure to TNF, a master proinflammatory 
cytokine, on protein aggregation in human induced pluripotent stem cell-derived neurons 
harbouring monogenic Alzheimers disease mutations. We report that exposure of 
Alzheimers disease, but not control, neurons to TNF induces substantial production of 
extracellular protein aggregates. Aggregates from Alzheimers disease neurons are composed 
of amyloid- and @?,)	 and induce significant permeabilisation of lipid membranes in 
an assay of pathogenicity. These findings provide support for a causal relationship between 
two crucial processes in Alzheimers disease pathogenesis, and suggest that targeting 
inflammation, particularly TNF, may have beneficial downstream effects on ameliorating 
aberrant protein aggregation and accumulation.
Keywords
Inflammation; protein aggregation; TNF; induced pluripotent stem cells; PSEN1
Abbreviations
AD  Alzheimers disease
ADPAINT - aptamer DNA points accumulation for imaging in nanoscale topography
A  amyloid-
CSF  cerebrospinal fluid
iPSC - induced pluripotent stem cell
MCI  mild cognitive impairment
SAVE - single aggregate visualisation by enhancement
TBI  traumatic brain injury
ThT  thioflavin T
TIRF  total internal reflection fluorescence
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3Introduction
Accumulation of misfolded proteins produced by neurons, initially extracellular deposits of ,	$?D EDF followed by intracellular aggregation of tau, are thought to be primary 
initiating mechanisms in Alzheimers disease (AD) pathogenesis (Hardy and Selkoe, 2002; 
Hardy and Higgins, 1992). Downstream of this biochemical phase of AD are complex 
interactions between neurons and astrocytes, microglia and other cell types, resulting in 
chronic neuroinflammation, synaptic dysfunction and eventually widespread cell loss (De 
Strooper and Karran, 2016). While inflammation in this context has been thought of as a 
reactive, secondary process, clinical, genetic and experimental evidence now suggests a more 
central upstream role for immune system involvement in AD pathophysiology and 
progression (reviewed in (Heneka et al., 2015), although how this initiates is not clear.
Several lines of evidence support the hypothesis that inflammation, either from the disease 
itself, or derived from secondary insults, augments pathology and cognitive decline in AD. 
First, increased levels of central and systemic proinflammatory cytokines are observed in 
mild cognitive impairment and are positively correlated with progression into severe AD 
(Bermejo et al., 2008; Tarkowski et al., 2003). Second, central neuroinflammation as a result 
of traumatic brain injury (TBI) speeds deposition of AD-associated proteins and cognitive 
impairment in animal models (Tajiri et al., 2013; Tran et al., 2011), while a putative 
epidemiological link has been established between TBI and future risk for AD (Dams-
O'Connor et al., 2016).  Finally, systemic inflammation is associated with higher levels of 
circulating proinflammatory cytokines and an increased rate of cognitive decline in AD 
patients (Dunn et al., 2005; Holmes et al., 2009), and accelerates primary neurodegenerative 
phenotypes, in particular protein aggregation and deposition, in animal models (Cunningham 
et al., 2009; Kyrkanides et al., 2011). The mechanisms underlying the relationship between a 
proinflammatory environment and primary disease phenotypes are yet to be fully elucidated, 
however.
We and others have reported that cortical excitatory neurons generated in vitro from iPSCs 
derived from individuals carrying disease-causing mutations in amyloid precursor protein 
(APP) or presenilin 1 (PSEN1) display robust and reproducible alterations in extracellular A 
species (Israel et al., 2012; Moore et al., 2015; Yagi et al., 2011), increased tau levels and 
https://mc.manuscriptcentral.com/braincom
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/b
ra
in
c
o
m
m
s
/a
d
v
a
n
c
e
-a
rtic
le
/d
o
i/1
0
.1
0
9
3
/b
ra
in
c
o
m
m
s
/fc
a
a
1
4
6
/5
9
0
6
0
2
0
 b
y
 g
u
e
s
t o
n
 0
6
 O
c
to
b
e
r 2
0
2
0
4phosphorylation (Israel et al., 2012; Moore et al., 2015), the production of synaptotoxic forms 
of Aand tau (Hung and Livesey, 2018).  Furthermore, neurons with mutations in PSEN1 or 
APP have pronounced dysregulation of the endolysosome autophagy network (Hung and 
Livesey, 2018), with no evidence of intracellular protein aggregation. Modelling of these 
monogenic, early onset cases of AD in human cellular systems has the potential to inform our 
understanding of the more common yet complex late onset form of the disease, while 
allowing for reductionist approaches toward elucidating complex interactions between 
disease pathways in sensitised genetic backgrounds. 
To investigate the relationship between inflammation and protein aggregation in AD, we 
exposed iPSC-derived AD neurons, which produce higher proportions of aggregation-prone 
A peptides, to the proinflammatory cytokine TNF, a key mediator common to both central 
and systemic inflammatory pathways, and measured changes in the production and 
composition of extracellular aggregates of disease-associated proteins. Using ultra-sensitive 
single-aggregate imaging techniques (Horrocks et al., 2016; Whiten et al., 2018b) and lipid 
permeabilisation assays (Flagmeier et al., 2017) capable of characterising the low 
concentration of secreted aggregates, we show that long-term treatment with TNF 
substantially increases the production of biologically active A and-synuclein-containing 
aggregates specifically in compromised familial AD neurons, but not healthy neurons, 
suggestive of a role for inflammation in early AD pathology. 
https://mc.manuscriptcentral.com/braincom
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5Materials and Methods
Generation of human cortical neuron cultures
The iPSC lines used in this study were non-demented control (NDC) and PSEN1 Intron4 and 
M146I, as previously reported (Moore et al., 2015). Pluripotent cells were maintained on 
Geltrex in Essential 8 media (both Thermofisher). With minor modifications to account for 
feeder free iPSC maintenance, directed differentiation to cerebral cortex was performed as 
previously described (Shi et al., 2012). Briefly, confluent monolayers of iPSCs were induced 
to form neural progenitors over the course of 12 days by dual-SMAD inhibition. Cortical 
progenitors were enriched and then expanded between days 12 and 35 post-neural induction 
before passaging onto Geltrex coated plates at a density of 80,000 cells per cm2 for neuronal 
differentiation and maturation.
TNF treatment
Treatments with recombinant human TNF at 0.1 and 10 ng/ml (Peprotech) or the vehicle 
control were started 60 days post-neural induction and continued for a duration of 18 d. 
During this period, a complete exchange of cell culture media was performed every 48 h. The 
secretomes of neuronal cultures were collected every 6 days, centrifuged at 800 RCF for 3 
min to remove cellular debris and stored at -20 °C until required for analysis. For washout 
experiments, cultures were switched from TNF treatment to the vehicle control after the 
collection of secretomes at day 12.
Multiplexed D ELISA
Quantification of D&J DL6 and DL was performed with the V-PLEX D peptide Panel 1 
kit (K15200E) and a Quickplex SQ120 instrument (MesoScale Discovery) using 25 µl of cell 
culture supernatant collected at day 18 of TNF treatment. 
Gene expression profiling of cortical cultures
To confirm the cortical identity of iPSC-derived neuronal cultures used in every experiment, 
Trizol-extracted RNA from day 18 vehicle-treated cultures of each genotype was profiled 
using a custom gene expression panel on the Nanostring platform (Nanostring Technologies). 
Mean negative control probe counts were subtracted from sample gene counts, before 
normalisation using the geometric mean of six positive control probes and seven 
housekeeping genes (CLTC, GAPDH, GUSB, PPIA, RPLP1, RPS15A, RPS9).
https://mc.manuscriptcentral.com/braincom
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6Cell viability assay
Live imaging of cell viability during the course of TNF treatment was performed by incubating 
the cultures with NUCLEAR-ID Blue/Red cell viability reagent (Enzo) diluted in culture media 
for 30 min, according to the manufacturers instructions. Cultures were washed in fresh 
media before images were acquired on an Opera Phenix imaging platform (Perkin Elmer) at 
37 °C and 5% CO2. For each timepoint, 37 fields of view were imaged at 20x objective in 
technical duplicate cultures of each treatment condition, with DAPI (ex375/em435-480) and 
dsRed (ex561/em570-630) laser and filter sets. For image processing, the number of red 
nuclei (indicating dead cells) was divided by the number of blue nuclei (indicating total cells) 
within each field of view to obtain a measure of the proportion of dead nuclei per condition. 
TIRF imaging
Imaging of the aggregates was performed using a purpose-built total internal reflection 
fluorescence (TIRF) microscope. The intensities of 405 nm (Oxxius Laser-Boxx, Oxxius), 488 
nm (TOPTICA Photonics) and 561 nm (Cobalt Jive, Cobalt) lasers were first attenuated using 
neutral density filters, circularly polarised using quarter wave plates, expanded using 
telescopes and then passed through appropriate filters (FF01-417/60-25 for 405 nm, LL01-
488-25 for 488 nm and FF01-561/14-25 for 561 nm, Semrock). The beams were then made 
concentric using dichroic mirrors (FF552-Di02-25x36 and FF458-Di02-25x36, Semrock) and 
directed into the back port of an inverted Ti-E Eclipse microscope (Nikon). The light was 
passed through a 1.49 N.A., 60x TIRF objective. Fluorescence was collected by the same 
objective, separated from excitation light using dichroic mirror (Di01-R405/488/561/635, 
Semrock) and passed through filters appropriate for the fluorophore (BLP01-488R-25 for 
ThT, BLP01-488R-25 for Cal-520 and LP02-568RS-25 for Cy3B, Semrock). The fluorescence 
was then expanded using a 2.5x relay lens and focussed onto an electron-multiplying charge-
coupled device for imaging. 
ADPAINT and SAVE imaging was performed as described previously (Whiten et al., 2018b). 
Briefly, round 50 mm slides first were cleaned under argon plasma (PDC-002, Harrick 
Plasma) for one hour. A CultureWell coverslip (CultureWell CWCS-50R-1.0, 50 channels) was 
then cut in half and layered on the slide to create individual wells. Each well was then 
incubated in aspartic acid (1 mg/ml) for 1 h to create a surface electrostatically unfavourable 
https://mc.manuscriptcentral.com/braincom
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7to DNA binding. The chambers were then rinsed with PBS, pH 7.4, 0.02 R filtered (Anotop25, 
Whatman) and the solution containing aggregates to be imaged incubated in the wells for 5 
min. For ADPAINT and SAVE imaging the cell culture media samples were first diluted 1:10 
in PBS. The solution was then aspirated and replaced with imaging solution, containing 100 
nM aptamer, 1 nM Cy3B-conjugated imaging strand and 5 µM ThT in Tris buffer. The 
chambers were then sealed using another clean coverslip to prevent evaporation. The 
sequences of the DNA strands are provided in Table 1. All DNA strands were diluted in PBS. 
To prevent user bias when imaging all images were taken in a grid using an automated script 
(Micro-Manager); exposure time for all frames was 50 ms. 4000 frames were acquired for 
ADPAINT imaging, for diffraction-limited imaging (including the single vesicle assay) 100 
frames were collected. Localisations were identified using the PeakFit ImageJ plugin of the 
GDSC Single Molecule Light Microscopy package using a signal strength threshold of 100 and 
a precision threshold of 20 nm. The DBSCAN algorithm in Python 3.7 (sklearn v0.20.1) was 
used to identify clusters and remove spurious localisations with epsilon = 3 and minimum 
points threshold = 10. Aggregate lengths were calculated by skeletonisation in Python 3.7 
using SciPy v1.1.0. The data analysis is described in detail in (Whiten et al., 2018b).
Membrane permeabilisation assay
The ability of the samples to permeabilise lipid membranes was performed as described 
previously (Flagmeier et al., 2017). This assay uses the fluorescence of Cal-520-filled vesicles 
immobilised on the glass coverslide to determine the relative influx of Ca2+ caused by the 
presence of protein aggregates. Cell culture media samples were used undiluted for these 
experiments and were incubated with the vesicles on the slides for 10 min before imaging. 
Antibodies/nanobodies were used to determine whether they could inhibit the 
permeabilisation and were preincubated with the media samples for 10 min at room 
temperature before incubation on the slide (see Table 2 for details of nanobodies and 
antibodies).
Statistical analysis
All statistical analysis was performed using Graphpad Prism 7. Unless otherwise stated, data 
was analysed with One or Two-way ANOVA, with additional post hoc testing performed using 
Dunnetts multiple comparison in the case of significant factor effects or interactions. Data 
shown in Supplementary Figure 3 were analysed using two sample Kolmogorov-Smirnov 
https://mc.manuscriptcentral.com/braincom
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8tests. Data shown in Figure panels 2B and 2C was analysed by one-sample t-test, comparing 
washout effects to non-washout effects, which were set to a baseline of 100%. Number of 
independent experiments is indicated in figure legends. 
Data availability
All primary data are provided in Supplementary Table 1.
https://mc.manuscriptcentral.com/braincom
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9Results
TNF induces increased secretion of aggregates by human PSEN1 mutant neurons 
We and others have reported that human stem cell-derived cortical neurons carrying 
mutations in PSEN1 that cause monogenic, familial Alzheimers disease alter production of 
extracellular D to longer, more aggregation-prone forms of the peptide (Moore et al., 2015; 
Yagi et al., 2011). To study the ability of inflammation to modify the production and 
aggregation of pathogenic proteins, we exposed human iPSC-derived cortical neurons to two 
different concentrations of TNF over a prolonged treatment period. Cortical neurons from a 
non-demented control (NDC) (Israel et al., 2012) and individuals carrying two different 
PSEN1 mutations (M146I and Intron 4) (Moore et al., 2015) were generated from iPSCs as 
previously described (Shi et al., 2012).  These two PSEN1 mutations were studied as they 
capture differing degrees of  deficits in endolysosomal function, with the M146I mutation 
having a more pronounced phenotype, in terms of changes in lysosome size and defects in 
autophagy (Hung and Livesey, 2018). 
Neurons were treated with either a vehicle control or TNF (0.1 ng/ml and 10 ng/ml; 
henceforth referred to as TNF low and TNF high, respectively). Preliminary experiments 
found that extracellular aggregates were clearly detected after 10-12 days, and robustly 
increased after 16-18 days of TNF treatment, therefore, in the experiments reported here, cell 
culture media were replaced every two days and collected every six days for analysis (Figure 
1A). These concentrations cover the physiological range of TNF reported in the human brain 
in chronic (Mogi et al., 1994) and acute (Waage et al., 1989) neuroinflammatory conditions, 
although the local concentration of TNF could be higher. The cortical identity of each neuronal 
differentiation was confirmed by multiplexed transcriptional profiling (Supplementary 
Figure 1). Data from a comprehensive single cell RNAseq analysis of neurons of each genotype 
had previously found that neurons express TNFR1, with no detectable expression of TNF or 
TNFR2 (Supplementary Figure 1).
It has previously been demonstrated that TNF can act directly to increase the activity of the 
APP promoter (Ge and Lahiri, 2002), the expression of D?) (Yamamoto et al., 2007) 
and the activity of -secretase (Liao et al., 2004), resulting in increased A production (Liao 
et al., 2004; Yamamoto et al., 2007). To examine the effects of TNF on the APP processing 
https://mc.manuscriptcentral.com/braincom
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10
pathway in human neurons, we analysed their secretomes with multiplexed A ELISAs after 
the 18-day treatment period. As previously reported (Moore et al., 2015), the ratio of 
A40/A42 was significantly impacted by genotype, reflecting the impaired -secretase 
activity of PSEN1 mutant neurons (Figure 1B). However, there was no significant change in 
the A40/A42 ratio (Figure 1B) or total AA	A
	A
production (Figure 1C) in 
response to TNFexposure, suggesting the APP processing pathway is not altered in this 
system by this treatment. 
In addition to the increased production of longer forms of A peptides, accumulation of 
extracellular aggregates comprising protein and peptide oligomers is considered an 
important pathogenic process in Alzheimers disease (Hardy and Selkoe, 2002; Hardy and 
Higgins, 1992).  Characterisation of the aggregates secreted by IPSC neurons is challenging 
due to their low concentrations and heterogeneous size distribution, such that bulk 
biochemical methods cannot be used, due to insufficient sensitivity. We therefore used two 
complementary biophysical imaging techniques to directly study the effect of TNF exposure 
on neuronal production of extracellular protein aggregates. Single aggregate visualisation by 
enhancement (SAVE) (Horrocks et al., 2016) uses thioflavin T (ThT) to enable the diffraction-
limited imaging of D??)1 aggregates in secretomes (Figure 1D). By contrast, 
aptamer DNA points accumulation for imaging in nanoscale topography (ADPAINT) (Whiten 
et al., 2018b) is a super-resolution technique that uses an oligonucleotide which recognises 
aggregates of D and @?,)	 (Tsukakoshi et al., 2012) and is visualised by the transient 
interactions of a complementary imaging strand (Figure 1E). 
Analysis of neural secretomes using both techniques revealed no significant difference in 
aggregate number between control and PSEN1 mutant neurons before TNF treatment 
(Supplementary Figure 2). The limit of our resolution is 20nm, which means that aggregates 
smaller than this size can still be detected but appear as 20 nm. However, the majority of the 
aggregates found here were larger than 20 nm and thus their size is accurately determined. 
We observed no significant changes in aggregate number in the secretomes of healthy control 
neurons following TNF exposure over the 18-day period, compared to vehicle controls, using 
both SAVE (Figure 1D) and ADPAINT (Figure 1E). In contrast, 18 days of both  TNF low and  
high treatment induced an increase in aggregate production by both PSEN1 M146I  (4-5 fold 
low and 6  9 fold increase high) and Intron 4 (8-9 fold low and 13  14 fold increase) neurons 
https://mc.manuscriptcentral.com/braincom
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using both imaging techniques (Figure 1D, E) with the high dose TNF treatment increase 
being statistically significant. These statistically significant increases in extracellular 
aggregates were not detected until after 18 days of treatment, indicating that this phenotype 
is dependent upon both the PSEN1 mutant genotypes employed and long-term exposure to 
TNF.
In addition to the number of aggregates, the size and conformation of assemblies is a 
determinant of their potential pathogenicity (Chiti and Dobson, 2017). We therefore used 
ADPAINT super resolution imaging to investigate changes in the size of individual aggregates 
in response to TNFexposure. In vehicle treated cultures, we observed that control neurons 
produce extracellular aggregates primarily between 20 nm (the size limit of the assay) and 
50 nm. PSEN1 mutant neurons produced significantly less aggregates in this size range, 
instead generating larger aggregates that spanned between 50 and 150 nm (Supplementary 
Figure 3A). This result correlates with our recent observations of a significant increase in 
large aggregates (40  200 nm) in the CSF of AD patients compared to that of healthy controls 
using the same assay (De et al., 2019). We observed a significant reduction in the size of 
aggregates produced specifically by PSEN1 mutant neurons after TNF exposure, although the 
magnitude of this effect size is small and does not bring the size distribution of the aggregates 
back in line with vehicle treated control cultures (Supplementary Figure 3).
Together, these data demonstrate that PSEN1 mutant neurons produce a comparable number 
of extracellular aggregates to controls in normal culture conditions, although the size of 
aggregates from PSEN1 mutants is significantly larger which means that they secrete a larger 
mass of aggregates than controls. PSEN1 mutant neurons specifically increase the production 
of extracellular aggregates in response to 18 days of TNFhigh exposure, with a small decrease 
in aggregate size observed compared to vehicle controls.
Aggregate secretion is not reversible following TNF withdrawal and is not due to cell death
As the effects of TNF on aggregate production were not acute and only observed at day 18 of 
our assays, we next assessed the requirement for continuous inflammatory stress in the 
production of this phenotype in a series of washout experiments. Aggregates were measured 
in the secretomes of cultures either continuously treated with TNF for 18 days or switched to 
the vehicle control at day 12 for the final six days, with complete media changes every two 
https://mc.manuscriptcentral.com/braincom
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days (Figure 2A). Aggregate production at day 18 was not statistically different between 
neurons continuously treated with either concentration of TNF and those switched to the 
vehicle control at day 12, when analysed by SAVE (Figure 2B) and ADPAINT (Figure 2C). 
Therefore, exposure of human PSEN1 mutant neurons to TNF initiates a process that 
manifests even after the subsequent removal of the stimulus. 
The signalling pathways of TNF in neurons are complex and have been reported to play both 
neuroprotective and detrimental roles (Probert, 2015). To test the possibility that 
extracellular aggregates were due to cell death via TNF signalling, we used a live/dead 
nuclear dye to quantify cell viability in cultures from each genotype across the course of the 
treatment by high content imaging.  Exposure to either low or high doses of TNF had no 
significant effect on cell death in control (Figure 2D) or PSEN1 mutant cultures (Figure 2E-F), 
indicating that reduced cell viability does not contribute to the observed increase in 
extracellular aggregates following TNF exposure. 
Aggregates produced by PSEN1 mutant neurons permeabilise lipid membranes and contain , 
and -. %)
Membrane permeabilisation is a primary mechanism by which extracellular protein 
aggregates have been hypothesised to confer toxicity (Demuro et al., 2005) by allowing the 
entry of calcium ions leading to disrupted calcium homeostasis (Dreses-Werringloer et al., 
2008). We used an ultrasensitive assay to measure the membrane permeabilisation activity 
of aggregates generated by human neurons, which we have previously validated with in vitro 
generated aggregates (Whiten et al., 2018a) and those found in CSF samples from AD patients 
(Drews et al., 2017). This assay quantifies the ability of aggregates to permeabilise the lipid 
bilayers of immobilised liposomes, permitting the influx of Ca2+ and the activation of an 
enclosed calcium-dependent fluorescent reporter, which is then normalised to ionomycin-
mediated lysis (Figure 3A). 
Secretomes from vehicle treated control cultures were limited in their ability to permeabilise 
membranes and TNF did not increase their potency (Figure 3B). Similarly, vehicle treated 
PSEN1 M146I (Figure 3C) and Intron 4 mutant secretomes (Figure 3D) were relatively inert 
in this assay. However, lipid membrane permeabilisation was significantly increased by 
secretomes from TNF low and high treated PSEN1 M146I mutant neurons (Figure 3C) and 
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from TNF high treated PSEN1 Intron 4 mutant neurons (Figure 3D), compared to their 
respective vehicle controls.  These results correlate with our SAVE and ADPAINT imaging 
data, and demonstrate that TNF treatment of PSEN1 mutant neurons, but not non-demented 
controls, augments the production of extracellular aggregates that have the capacity to 
permeabilise lipid membranes and hence have a detrimental effect on neurons. 
We have previously demonstrated that the composition of protein aggregates with activity in 
this assay can be directly determined by pre-incubation with candidate neutralising 
nanobodies and antibodies (De et al., 2019; Drews et al., 2017). Using this approach, the 
composition of extracellular aggregates was investigated by pre-incubating the secretomes 
from TNF-treated PSEN1 mutant neurons with nanobodies or antibodies to D @?,)	 
and tau, all of which form aggregates in neurodegenerative diseases and are released by 
neurons in culture (Evans et al., 2018; Moore et al., 2015). 
Pre-incubation with an D?)-) nanobody (Nb3) (Paraschiv et al., 2013) significantly and 
substantially reduced membrane permeabilisation by TNF-treated AD neuron secretomes 
from PSEN1 M146I (reduction of 31.0%  1.9%) (Figure 3E) and Intron 4 (reduction of 58.7% 
 2.3%) mutants (Figure 3F). Pre-incubation with an @?,)	?)-) nanobody 
(NbSyn2) (Iljina et al., 2017) also significantly reduced membrane permeabilisation by the 
secretomes of TNF-treated PSEN1 M146I (reduction of 14.2%  6.7%) (Figure 3E) and PSEN1 
Intron 4 neurons (reduction of 32.7%  0.9%) (Figure 3F) but by a smaller margin than Nb3. 
In contrast, pre-incubation with two tau-directed antibodies that bind to different epitopes 
had no significant effect, suggesting that tau does not form or contribute to the toxic 
aggregates produced under these conditions. Together, these results suggest that TNF 
augments the secretion of extracellular D and -synuclein containing aggregates from 
PSEN1 mutant neurons that have the capacity to permeabilise lipid membranes.
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Discussion
We report here that chronic TNF treatment of human PSEN1 mutant neurons, but not healthy 
control neurons, results in increased release of toxic extracellular protein aggregates. Using 
single molecule imaging techniques and membrane permeabilisation assays, we determined 
that these aggregates contain A and/or -synuclein, potentially with other proteins, and 
have the capacity to permeabilise lipid membranes. We previously observed an increase in 
the ability of aggregates in CSF to permeabilise membranes with no accompanying change in 
aggregate number when comparing patients who are mildly cognitively impaired (MCI) and 
hence at the early stages of developing AD compared to controls (De et al., 2019). 
Furthermore, using ADPAINT, we found that this increased membrane permeabilisation 
corresponded with an increase in the proportion of smaller aggregates present in the MCI 
CSF, similar to the changes observed here in the aggregate size distribution on exposure of 
mutant neurons to TNF.  
Due to the high concentration of peptide required for oligomerisation, it is presumed that A 
aggregates in vivo are formed intracellularly (Friedrich et al., 2010; Hu et al., 2009). In this 
study, the extracellular concentration of monomeric A42 in PSEN1 mutant secretomes was 
not modified by TNF treatment, and never exceeded 20 pM, which is far below the nanomolar 
concentrations required for fibril formation (Novo et al., 2018), suggesting an intracellular 
origin for extracellularly detected aggregates. In addition to A we also determined that -
synuclein was an aggregate constituent, which may be explained by previous observations 
that A42 has specific interactions with -synuclein, which can result in bilateral aggregation 
of each species (Mandal et al., 2006; Masliah et al., 2001). The presence of A and -synuclein 
co-aggregates in TNF treated PSEN1 secretomes also cannot be excluded and has been 
observed in vitro (Iljina et al., 2018). 
The increased release of aggregates following TNF treatment is independent of cell death, 
suggesting a regulated mechanism of release from genetically vulnerable neurons. We have 
previously shown that in addition to altered Aproduction, neurons harbouring PSEN1 
mutations have impaired endolysosomal function, which manifests as a pronounced defect in 
the degradative phase of autophagy (Hung and Livesey, 2018). We hypothesise perturbed 
proteostasis due to altered endolysosomal trafficking and reduced autophagy may render 
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neurons susceptible to aberrant aggregate generation and exocytosis in the presence of an 
additional trigger. How TNF acts as that trigger is currently not clear, but it is notable that 
TNF-TNFR signalling regulates autophagy in other cell types (Ge et al., 2018) ,which may 
further aggravate the pre-existing defects in the autophagy-lysosomal network in PSEN1 
mutant neurons, promoting protein aggregation and release.
The aggregate size distribution that we measure for the mutant neurons, exposed to TNF, is 
notably similar to that we recently measured in MCI and AD CSF (Figure S2C), using the same 
imaging method (De et al., 2019). This suggests that similar secretion of aggregates occurs in 
vivo during the development of AD as observed from human neurons in vitro. Increased 
aggregate secretion may be a major mechanism for neurons to maintain protein homeostasis 
under stress, as well as a major source of A monomer (Wang et al., 2017). 
Higher concentrations of longer protofibillar aggregates of Awith sizes in the same range 
as detected in these experiments (40-200 nm), have previously been shown to cause an 
inflammatory response via TLR4, leading to production of proinflammatory cytokines 
including TNF (Colvin et al., 2017; Paranjape et al., 2013; Terrill-Usery et al., 2016). A positive 
cycle of increased secretion of aggregates leading to increased inflammation and production 
of TNF and other pro-inflammatory cytokines could therefore drive increased production of 
A aggregates in the AD brain.  Therefore, the increase in number of Aaggregates that we 
observe in the presence of TNFtreatment provides a plausible mechanism for the three-fold 
increase in Aaggregates deposited in the AD brain over time (Roberts et al., 2017). Future 
experiments will need to establish if the same increase in number of aggregates occurs in 
wild-type neurons, as well as mutant neurons, when exposed to TNF over longer times.   In 
addition to its role as a modulator of systemic and central inflammation, TNFis a key 
regulator of processes in neuronal development and homeostasis, primarily through 
signalling via the TNF receptor 1 (TNFR1) on neurons (Santello and Volterra, 2012), which is 
the only TNF receptor expressed in the human iPSC-derived neurons studied here. It has been 
demonstrated that TNFR1 signalling can modulate synaptic strength via exocytosis of AMPA 
receptors (Beattie et al., 2002; Stellwagen et al., 2005), and endocytosis of GABA receptors 
(Stellwagen et al., 2005), which may point to overlapping pathways involved in trafficking 
and exocytosis of protein aggregates in already vulnerable AD neurons in this case. Future 
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studies will be directed towards elucidating the cellular mechanisms linking TNF signalling 
and the production and release of protein aggregates specifically from AD neurons.
The amyloid cascade hypothesis, which proposes that aggregation of A is the central 
pathological event in AD pathogenesis (Hardy and Selkoe, 2002; Hardy and Higgins, 1992), 
has directed clinical efforts to treat the condition over the past several decades. While there 
have been a number of high profile clinical failures in this domain (Doody et al., 2013; Selkoe, 
2019), there remains significant interest in understanding the mechanisms and pathways 
leading to protein aggregation, which represents a shared pathogenic pathway in many 
neurodegenerative conditions. It is becoming accepted that in addition to protein 
aggregation, inflammation is a key element of early AD pathogenesis (Mhatre et al., 2015). In 
line with this, preclinical and clinical evidence suggests that targeting inflammation - TNFin 
particular - is a promising therapeutic avenue. In animal models of AD, selective ablation of 
microglia, the primary source of proinflammatory cytokines in the CNS, or inhibition of TNF 
signalling, significantly reduces A deposition while rescuing cognitive defects (He et al., 
2007; Shi et al., 2011; Sosna et al., 2018). Promising results from epidemiological studies and 
small scale clinical trials also suggest that exposure to anti-TNF agents reduces incidence or 
severity of AD in humans, though there is scope for future large scale randomised clinical 
trials to confirm these, at times, contradictory results (Ekert et al., 2018). 
Having established that TNF promotes protein aggregate production from monogenic AD 
neurons, which both generate longer, hydrophobic forms of A and have dysfunction of their 
endolysosomal-autophagy network, a wide range of follow up studies will be of interest. This 
includes exploring the cellular mechanisms underlying this process, the effect of other AD 
associated mutations and if similar changes can be observed in the control neuron, if exposed 
to TNF or a combination of pro-inflammatory cytokines for longer times. It will also be of 
interest to investigate the potential pro-inflammatory properties of the secreted aggregates 
and their capability to cause LTP deficit in rodent models. 
Overall, our results point to complex interactions during AD initiation in vivo, with early stage 
inflammation, either from the disease itself, or secondary insults, leading to TNF release and 
subsequent acceleration of the release of protein aggregates, which in turn drives further 
disease progression. Consequently, directly targeting these aggregates and reducing the 
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levels of TNF and other inflammatory cytokines are both potential therapeutic targets for 
slowing AD pathogenesis and may be more effective when used in combination. Finally, 
studies of iPSC-derived neurons in the presence of chronic levels of TNF may be a more 
realistic model of AD than studying neurons in the absence of any cellular stress, since the 
secreted aggregates have similar size distributions to AD CSF and show an increase in number 
as observed in AD.  
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FIGURE LEGENDS
Figure 1. TNF induces production of extracellular aggregates by human PSEN1 mutant 
neurons
(A) iPSC-derived neurons were exposed to TNF or vehicle for 18 days, with media collected 
every six days for analysis. (B) ELISA measurements of extracellular A revealed a significant 
impact of genotype, but not chronic TNF treatment, on A40/A42 ratio (Two-way ANOVA; 
Genotype factor F(2, 15) = 28.32, p<0.0001, Treatment factor F(2, 15) = 1.024, p > 0.05, Interaction 
F(4, 15) = 0.04128, p > 0.05). (C) Similarly, there was no significant dose-dependent change in 
total extracellular A (A38 + A40 + A42) as a result of chronic TNF exposure (Two-way 
ANOVA; Genotype factor F(2, 9) = 1.467, p > 0.05, Treatment factor F(1, 9) = 1.010, p > 0.05, 
Interaction F(2, 9) = 0.7066, p > 0.05). (D) SAVE imaging allows the imaging and quantification 
of individual ThT-positive D? containing aggregates from neural secretomes. SAVE 
imaging of control secretomes revealed no effect of TNF on aggregate number (Two-way 
ANOVA; Time factor F(2, 15) = 4.188, p < 0.05, Treatment factor F(2, 15) = 1.350, p > 0.05, 
Interaction F(4, 15) = 1.161, p > 0.05, all multiple comparisons p > 0.05). By contrast, high dose 
TNF significantly increased the number of aggregates in the secretomes of PSEN1 M146I 
(Two-way ANOVA; Time factor F(2, 15) = 18.60, p < 0.0001, Treatment factor F(2, 15) = 4.048, p < 
0.05, Interaction F(4, 15) = 2.321, p > 0.05) and Intron 4 (Two-way ANOVA; Time factor F(2, 15) = 
7.943, p < 0.01, Treatment factor F(2, 15) = 2.752, p > 0.05, Interaction F(4, 15) = 1.536, p > 0.05) 
mutant neuronal cultures.  (E) ADPAINT imaging uses aptamers that recognise D and @?
synuclein oligomers, which transiently interact with complementary imaging strands to 
enable detection of aggregates using super resolution microscopy. ADPAINT imaging of the 
same secretomes confirmed that TNF had no effect on the production of aggregates from 
control neurons (Two-way ANOVA; Time factor F(2, 15) = 1.217, p > 0.05, Treatment factor F(2, 
15) = 0.8401, p > 0.05, Interaction F(4, 15) = 0.03294, p > 0.05), however high doses resulted in 
a significant increase in aggregates produced by PSEN1 M146I (Two-way ANOVA; Time factor 
F(2, 15) = 22.38, p < 0.0001, Treatment factor F(2, 15) = 3.819, p < 0.05, Interaction F(4, 15) = 2.424, 
p > 0.05) and Intron 4 (Two-way ANOVA; Time factor F(2, 15) = 11.15, p < 0.01, Treatment 
factor F(2, 15) = 2.609, p > 0.05, Interaction F(4, 15) = 1.838, p > 0.05) mutant neurons. Data in D,E 
are represented as a fold change in aggregate number from day 0 baseline. N = 3 independent 
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experiments in all cases. Error bars represent S.D. In D-E * = p < 0.05, ** = p < 0.01 versus 
vehicle control, Dunnetts multiple comparisons. 
Figure 2. Augmented extracellular aggregate production continues following TNF 
withdrawal and is not due to increased cell death
(A) TNF was removed at day 12 of treatment by switching a subset of cultures to the vehicle 
control, with media changed every two days to ensure complete washout. SAVE (B) and 
ADPAINT (C) imaging of secretomes subjected to TNF removal and washout at day 12 
revealed comparable number of aggregates to those cultures treated for a full 18 days (One 
sample t test vs. 100%, p > 0.05 in all cases). (D  F) High content imaging revealed no 
significant changes in cell viability in control (D) (Two-way Repeated-measures ANOVA; 
Time factor F(3, 9) = 3.966, p < 0.05, Treatment factor F(2, 3) = 0.09118, p > 0.05, Interaction F(6, 
9) = 0.3276, p > 0.05, all multiple comparisons p > 0.05), PSEN1 M146I (E) (Two-way 
Repeated-measures ANOVA; Time factor F(3, 9) = 1.554, p > 0.05, Treatment factor F(2, 3) = 
4.394, p > 0.05, Interaction F(6, 9) = 0.09461, p > 0.05) or Intron 4 (F) (Two-way Repeated-
measures ANOVA; Time factor F(3, 9) = 3.092, p > 0.05, Treatment factor F(2, 3) = 0.03124, p > 
0.05, Interaction F(6, 9) = 0.2670, p > 0.05) mutant neurons as a result of TNF treatment when 
assessed by cell viability dye. Data in B and C are represented as a percentage of the aggregate 
number in washout conditions at day 18 compared with continuous 18-day TNF treatment in 
each case. N = 2 independent experiments in all assays. Error bars represent S.D.   
Figure 3. Aggregates are composed of 2 and 3	
 and permeabilise lipid 
membranes
(A) The single-vesicle permeabilisation assay consists of a preparation of liposomes loaded 
with a fluorescent Ca2+ detection dye (Cal-520), which fluoresce after protein aggregates 
disrupt the membrane and allow the entry of Ca2+. Ionomycin induces maximal 
permeabilisation and is used to benchmark liposome responses to aggregates as a percentage 
of total possible Ca2+ influx. (B  D) Exposure of liposomes to day 18 treated neural 
secretomes revealed that secretomes from control neurons (B) did not induce 
permeabilisation of liposomes (One-way ANOVA; F(2, 5) = 0.8862, p > 0.05), but those from 
TNF-treated PSEN1 M146I (C) (One-way ANOVA; F(2, 5) = 30.87, p < 0.01) and Intron 4 (D) 
(One-way ANOVA; F(2, 5) = 22.49, p < 0.01) mutant neurons induced significant liposome 
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disruption, consistent with the presence of increased numbers of protein aggregates. (E, F) 
Pre-incubation of TNF high-treated neural secretomes with nanobodies to D (Nb3) and @?
synuclein (NbSyn2) significantly reduced the permeabilisation potential of the secretomes 
from PSEN1 M146I (E) (One-way ANOVA; F(5, 6) = 36.25, p < 0.001) and Intron 4 (F) (One-way 
ANOVA; F(5, 6) = 162.1, p < 0.0001) mutant neurons, while pre-incubation with control IgG or 
two tau-directed antibodies (Tau 5 and HT7) had no significant effect. N = 3 independent 
experiments in B-D, and N = 2 independent liposome preparations in E-F. Error bars 
represent S.D. In B-D, * = p < 0.05 and ** = p < 0.01 versus vehicle treatment, Dunnetts 
multiple comparisons. In E-F * = p < 0.05, *** = p < 0.001 and **** = p < 0.0001 versus no 
antibody preincubation, Dunnetts multiple comparisons.
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 Figure 1. TNF induces production of extracellular aggregates by human PSEN1 mutant neurons 
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 Figure    Augmented extracellular aggregate production continues following TNF withdrawal and is not due 
to increased cell death 
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 and permeabilise lipid membranes 
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Table 1	 
es of DNA constructs used in this wo
DNA strand name 
e
Aptamer  n 
docng strand
GCCTGTGGTGTTGGGGCGGGTGCGTTATACATCTA
Imaging strand CCAGATGTAT-CY3B
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Table 2 tibodies and nanobodies used in single vesicle assays.
Antibody Target Supplier Concentration 
used
N3 	
 Prof. Serge Muyldermans, Vrije 
Universiteit Brussel, Belgium
300 nM
NSyn2  	! Dr Marija Iljina, University of 
Cambridge, UK
300 nM
Hff Tau Thermo Fisher Scientific 
(MN1000)
300 nM
Tfiflffi
Tau Abcam (ab3931) 300 nM
IgG control N/A Abcam (ab6556) 300 nM
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Abbreviated Summary
There is a complex interplay between neuroinflammation and protein aggregation in Alzheimers 
disease. We show that chronic exposure to the inflammatory cytokine TNF stimulates monogenic 
Alzheimers disease neurons to produce significantly more toxic protein aggregates, with no effect on 
healthy neurons, indicating a causal relationship between neuroinflammation and protein 
aggregation.
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